Kentucky Retirement Systems Has $29.02 Million Holdings in Merck & Co., Inc. $MRK

Kentucky Retirement Systems grew its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 52.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 241,239 shares of the company's stock after acquiring an additional 83,043 shares during the quarter. Merck & Co., Inc. comprises 1.0% of Kentucky Retirement Systems' holdings, making the stock its 19th largest holding. Kentucky Retirement Systems' holdings in Merck & Co., Inc. were worth $29,019,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Kingdom Financial Group LLC. bought a new stake in Merck & Co., Inc. during the 4th quarter valued at $25,000. Abound Financial LLC bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at $26,000. Prosperity Bancshares Inc acquired a new position in shares of Merck & Co., Inc. during the fourth quarter valued at about $26,000. High Note Wealth LLC grew its holdings in shares of Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company's stock valued at $31,000 after buying an additional 109 shares during the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new stake in shares of Merck & Co., Inc. during the fourth quarter worth about $31,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on MRK shares. Wall Street Zen lowered shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating in a report on Monday, July 20th. BMO Capital Markets lifted their price target on Merck & Co., Inc. from $135.00 to $142.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. Bank of America increased their price objective on Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a "buy" rating in a research note on Tuesday, June 30th. Wells Fargo & Company raised their target price on Merck & Co., Inc. from $145.00 to $150.00 and gave the company an "overweight" rating in a report on Wednesday, July 8th. Finally, CICC Research started coverage on Merck & Co., Inc. in a research report on Wednesday, June 24th. They set an "outperform" rating and a $138.00 target price on the stock. Thirteen analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $134.50.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $130.45 on Thursday. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The firm has a 50-day moving average of $122.73 and a 200-day moving average of $118.24. Merck & Co., Inc. has a one year low of $77.53 and a one year high of $135.05. The company has a market cap of $322.18 billion, a P/E ratio of 36.75, a P/E/G ratio of 5.23 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion for the quarter, compared to analysts' expectations of $15.85 billion. During the same period in the previous year, the company earned $2.22 earnings per share. The firm's revenue for the quarter was up 4.9% compared to the same quarter last year. Equities research analysts forecast that Merck & Co., Inc. will post 2.74 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.6%. Merck & Co., Inc.'s dividend payout ratio (DPR) is currently 95.77%.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Barclays raised its price target to $150 from $140 and maintained an “overweight” rating, implying roughly 15% upside from the referenced price. The increase reflects continued confidence in Merck’s outlook. Barclays raises Merck price target
• Positive Sentiment: KEYTRUDA met its primary progression-free-survival endpoint in a Phase 3 trial for advanced or recurrent endometrial cancer, outperforming platinum-based chemotherapy. Merck said the result could support future regulatory filings and strengthen its oncology pipeline. Merck KEYTRUDA endometrial cancer trial
• Positive Sentiment: Merck announced its fourth-quarter 2026 dividend, reinforcing the stock’s appeal to income-oriented investors and signaling continued capital-return support. The provided announcement did not include the dividend amount or payment details. Merck fourth-quarter dividend announcement
• Neutral Sentiment: Wells Fargo reiterated its Buy rating, while broader brokerage coverage places Merck at a “Moderate Buy” consensus, indicating generally favorable but not universally bullish sentiment. Wells Fargo maintains Merck Buy rating
• Negative Sentiment: Analysts expect Merck’s second-quarter earnings to decline, and a Zacks preview says the company lacks the typical signals associated with a likely earnings beat. This raises near-term execution risk ahead of the earnings report. Merck second-quarter earnings preview

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.